

Reference FOIAH2425/115

Number:

From: Private Individual

Date: 23 May 2024

Subject: Multiple Sclerosis Treatment

- Q1 How many patients has your trust treated in the past six months (for any disease) with the following drugs:
- A1 Information not held the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q2 How many patients has you trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?
- A2 Information not held the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q3 How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?
- A3 13
- Q4 Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:

Condition	Patient Number
RRMS – Relapse Remitting Multiple Sclerosis	
PPMS – Primary Progressive Multiple Sclerosis	
SPMS – Secondary Progressive Multiple Sclerosis	

A4 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. Patients are not coded in a way that we could provide a breakdown as requested.